Trial reportAlcohol and alcoholism (Oxford, Oxfordshire)2026
Effects of cannabidiol on risky decision-making and autonomic function in alcohol use disorder.
Trial report in Alcohol and alcoholism (Oxford, Oxfordshire), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimsTo examine the effects of cannabidiol (CBD) on psychophysiological responding and risky decision-making in individuals with alcohol use disorder (AUD).
methodsIn a double-blind, placebo-controlled crossover trial, 18 participants with AUD completed the Columbia Card Task (CCT) following administration of CBD and placebo. Skin conductance responses (SCR) and high-frequency heart rate variability (HF-HRV) were assessed as indices of autonomic responding during task performance. Risk-taking was indexed by the number of cards selected on the CCT.
resultsCBD did not significantly affect SCR (P = .16, pBH = .326) or risky decision-making on the CCT (P > .63, pBH = 0.67). However, CBD significantly increased HF-HRV (β = 0.53, SE = 0.19, P = .005; pBH = 0.020). There was no evidence that the relationships between HF-HRV or SCR and risky decision-making differed between CBD and placebo conditions (drug × HF-HRV: P = .92; drug × SCR: P = .958; both pBH = .958). DISCUSSION: CBD increased HF-HRV but did not significantly alter SCR, risky decision-making, or the relationship between autonomic responses and risky decision-making. These findings suggest that CBD influences autonomic responding during task performance, although the functional significance of this effect remains uncertain. The modest sample size and relatively healthy, non-treatment-seeking sample may have limited the ability to detect broader physiological and behavioural effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.